{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T14:51:54Z","timestamp":1780843914312,"version":"3.54.1"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.addr.2022.114282","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T21:09:35Z","timestamp":1649711375000},"page":"114282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Altered peripheral factors affecting the absorption, distribution, metabolism, and excretion of oral medicines in Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"185","author":[{"given":"Elka S.","family":"Waller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Yardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Yun","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue Yi","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua H.","family":"Abasszade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Nicolazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.addr.2022.114282_b0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/1039856218762308","article-title":"Alzheimer's disease: Clinical update on epidemiology, pathophysiology and diagnosis","volume":"26","author":"Eratne","year":"2018","journal-title":"Australas Psychiatry"},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0010","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment combinations for Alzheimer's disease: Current and future pharmacotherapy options","volume":"67","author":"Cummings","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.addr.2022.114282_b0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1071\/AH18022","article-title":"Simulation of health care and related costs in people with dementia in Australia","volume":"43","author":"Standfield","year":"2019","journal-title":"Aust. Health Rev."},{"key":"10.1016\/j.addr.2022.114282_b0020","doi-asserted-by":"crossref","unstructured":"2021 Alzheimer's disease facts and figures. Alzheimer\u2019s Dement 17 (2021) 327\u2013406.","DOI":"10.1002\/alz.12328"},{"issue":"9","key":"10.1016\/j.addr.2022.114282_b0025","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2174\/1567205013666160314150501","article-title":"Molecular basis of familial and sporadic Alzheimer's disease","volume":"13","author":"Dorszewska","year":"2016","journal-title":"Curr. Alzheimer Res."},{"issue":"5580","key":"10.1016\/j.addr.2022.114282_b0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114282_b0035","unstructured":"Australian Government Department of Health. Pharmaceutical Benefits Scheme (PBS). Accessed December 20, 2021. https:\/\/www.pbs.gov.au\/browse\/body-system?depth=3&codes=n06d#n06d."},{"key":"10.1016\/j.addr.2022.114282_b0040","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/bmj.n1682","article-title":"Aducanumab for Alzheimer\u2019s disease?","volume":"374","author":"Walsh","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.addr.2022.114282_b0045","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of aducanumab for Alzheimer disease - the FDA\u2019s perspective","volume":"10","author":"Dunn","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.addr.2022.114282_b0050","unstructured":"Australian Medicines Handbook Pty Ltd. Australian medicines handbook (online) - Alzheimer\u2019s disease. Accessed December 23, 2021. https:\/\/amhonline.amh.net.au\/auth."},{"issue":"5","key":"10.1016\/j.addr.2022.114282_b0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/09687688.2014.937468","article-title":"The blood-brain barrier: Structure, function and therapeutic approaches to cross it","volume":"31","author":"Tajes","year":"2014","journal-title":"Mol. Membr. Biol."},{"issue":"1","key":"10.1016\/j.addr.2022.114282_b0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"12","key":"10.1016\/j.addr.2022.114282_b0065","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"issue":"8","key":"10.1016\/j.addr.2022.114282_b0070","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s11095-009-9896-0","article-title":"Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs","volume":"26","author":"Matsson","year":"2009","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.addr.2022.114282_b0075","doi-asserted-by":"crossref","first-page":"e0250371","DOI":"10.1371\/journal.pone.0250371","article-title":"Transport of Alzheimer\u2019s associated amyloid-\u03b2 catalyzed by P-glycoprotein","volume":"16","author":"McCormick","year":"2021","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.addr.2022.114282_b0080","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1148\/radiol.2016152244","article-title":"Blood-brain barrier leakage in patients with early Alzheimer disease","volume":"281","author":"van de Haar","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.addr.2022.114282_b0085","doi-asserted-by":"crossref","first-page":"8845","DOI":"10.1523\/JNEUROSCI.6102-11.2012","article-title":"A\u03b2(1\u201342)-RAGE interaction disrupts tight junctions of the blood\u2013brain barrier via Ca2+-calcineurin signaling","volume":"32","author":"Kook","year":"2012","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.addr.2022.114282_b0090","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.26134","article-title":"Blood-brain barrier breakdown in relationship to Alzheimer and vascular disease","volume":"90","author":"Lin","year":"2021","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.addr.2022.114282_b0095","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2967\/jnumed.113.130161","article-title":"Activity of P-glycoprotein, a \u03b2-amyloid transporter at the blood\u2013brain barrier, is compromised in patients with mild Alzheimer disease","volume":"55","author":"Deo","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.addr.2022.114282_b0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.brainres.2010.08.034","article-title":"ABC efflux transporters in brain vasculature of Alzheimer\u2019s subjects","volume":"1358","author":"Wijesuriya","year":"2010","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0105","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/cpt.2035","article-title":"Abundance of P-glycoprotein and other drug transporters at the human blood-brain barrier in Alzheimer\u2019s disease: A quantitative targeted proteomic study","volume":"109","author":"Storelli","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114282_b0110","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/mol.109.061754","article-title":"Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease","volume":"77","author":"Hartz","year":"2010","journal-title":"Mol. Pharmacol."},{"issue":"11","key":"10.1016\/j.addr.2022.114282_b0115","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1007\/s11095-013-1116-2","article-title":"Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer\u2019s disease","volume":"30","author":"Mehta","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114282_b0120","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1523\/JNEUROSCI.5103-08.2009","article-title":"ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1\u201340) peptides","volume":"29","author":"Xiong","year":"2009","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.addr.2022.114282_b0125","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1007\/s11095-017-2263-7","article-title":"Disease-induced alterations in brain drug transporters in animal models of Alzheimer\u2019s disease","volume":"34","author":"Vellonen","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114282_b0130","first-page":"33","article-title":"Comorbidity and polypharmacy in people with dementia: Insights from a large, population-based cross-sectional analysis of primary care data","volume":"46","author":"Clague","year":"2016","journal-title":"Age Ageing"},{"key":"10.1016\/j.addr.2022.114282_b0135","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.3390\/ijerph17103398","article-title":"Prevalence of comorbidities in individuals diagnosed and undiagnosed with Alzheimer's disease in Leon, Spain and a proposal for contingency procedures to follow in the case of emergencies involving people with Alzheimer's disease","volume":"17","author":"Tortajada-Soler","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"1","key":"10.1016\/j.addr.2022.114282_b0140","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2042098612469335","article-title":"The ABCD of clinical pharmacokinetics","volume":"4","author":"Doogue","year":"2013","journal-title":"Ther. Adv. Drug. Saf."},{"issue":"1","key":"10.1016\/j.addr.2022.114282_b0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bcp.2013.09.007","article-title":"Pharmacokinetics","volume":"87","author":"Fan","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2022.114282_b0150","series-title":"Biochemistry, Biotransformation","author":"Phang-Lyn","year":"2020"},{"key":"10.1016\/j.addr.2022.114282_b0155","doi-asserted-by":"crossref","unstructured":"S.K. Bardal, J.E. Waechter, D.S. Martin, Chapter 2 - pharmacokinetics, W.B. Saunders, Philadelphia, 2011, pp. 17\u201334.","DOI":"10.1016\/B978-1-4377-0310-8.00002-6"},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0160","doi-asserted-by":"crossref","first-page":"M173","DOI":"10.1093\/gerona\/57.3.M173","article-title":"Prevalence and impact of medical comorbidity in Alzheimer's disease","volume":"57","author":"Doraiswamy","year":"2002","journal-title":"J. Gerontol. A"},{"issue":"450","key":"10.1016\/j.addr.2022.114282_b0165","first-page":"e7","article-title":"Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: Results from the Shelter study","volume":"14","author":"Onder","year":"2013","journal-title":"JAMDA"},{"key":"10.1016\/j.addr.2022.114282_b0170","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neurobiolaging.2019.05.025","article-title":"Temporal progression of Alzheimer's disease in brains and intestines of transgenic mice","volume":"81","author":"Manocha","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.addr.2022.114282_b0175","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neurobiolaging.2020.04.009","article-title":"Probiotics ameliorate intestinal pathophysiology in a mouse model of Alzheimer\u2019s disease","volume":"92","author":"Kaur","year":"2020","journal-title":"Neurobiol. Aging"},{"issue":"1-3","key":"10.1016\/j.addr.2022.114282_b0180","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejphar.2004.07.054","article-title":"In vivo and in vitro study of the influence of the anticholinesterase drug galantamine on motor and evacuative functions of rat gastrointestinal tract","volume":"498","author":"Turiiski","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.addr.2022.114282_b0185","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fmicb.2016.00455","article-title":"Gut microbiota diversity and human diseases: Should we reintroduce key predators in our ecosystem?","volume":"7","author":"Mosca","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2022.114282_b0190","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bbi.2019.05.008","article-title":"Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort","volume":"80","author":"Liu","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.addr.2022.114282_b0195","doi-asserted-by":"crossref","first-page":"13537","DOI":"10.1038\/s41598-017-13601-y","article-title":"Gut microbiome alterations in Alzheimer's disease","volume":"7","author":"Vogt","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114282_b0200","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3390\/ijms21051711","article-title":"Dysregulated gut homeostasis observed prior to the accumulation of the brain amyloid-\u03b2 in Tg2576 mice","volume":"21","author":"Honarpisheh","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.addr.2022.114282_b0205","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3233\/JAD-160926","article-title":"Altered gut microbiome composition and tryptic activity of the 5xFAD Alzheimer\u2019s mouse model","volume":"56","author":"Brandscheid","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.addr.2022.114282_b0210","doi-asserted-by":"crossref","first-page":"41802","DOI":"10.1038\/srep41802","article-title":"Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota","volume":"7","author":"Harach","year":"2017","journal-title":"Sci. Rep."},{"issue":"1-2","key":"10.1016\/j.addr.2022.114282_b0215","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jneuroim.2008.09.017","article-title":"Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS)","volume":"206","author":"Zhang","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.addr.2022.114282_b0220","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fcimb.2020.00248","article-title":"The role of the gastrointestinal mucus system in intestinal homeostasis: Implications for neurological disorders","volume":"10","author":"Madushani","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"6","key":"10.1016\/j.addr.2022.114282_b0225","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bpg.2017.10.001","article-title":"Action and function of Akkermansia muciniphila in microbiome ecology, health and disease","volume":"31","author":"Ottman","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"9","key":"10.1016\/j.addr.2022.114282_b0230","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1194\/jlr.R036012","article-title":"The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism","volume":"54","author":"den Besten","year":"2013","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0235","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s12035-018-1188-4","article-title":"The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer's disease\u2014a critical review","volume":"56","author":"Sochocka","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.addr.2022.114282_b0240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40035-018-0107-y","article-title":"Alzheimer's disease hypothesis and related therapies","volume":"7","author":"Du","year":"2018","journal-title":"Transl Neurodegener."},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0245","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ane.13196","article-title":"C-type lectin-like receptor 2 and zonulin are associated with mild cognitive impairment and Alzheimer's disease","volume":"141","author":"Wang","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.addr.2022.114282_b0250","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1749-6632.2012.06538.x","article-title":"Zonulin, regulation of tight junctions, and autoimmune diseases","volume":"1258","author":"Fasano","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.addr.2022.114282_b0255","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1053\/gast.2002.36578","article-title":"Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure","volume":"123","author":"Asmar","year":"2002","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.addr.2022.114282_b0260","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1021\/acs.molpharmaceut.9b01227","article-title":"Intestinal permeability and oral absorption of selected drugs are reduced in a mouse model of familial Alzheimer\u2019s disease","volume":"17","author":"Jin","year":"2020","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.addr.2022.114282_b0265","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1021\/acs.molpharmaceut.8b00500","article-title":"Altered expression of small intestinal drug transporters and hepatic metabolic enzymes in a mouse model of familial Alzheimer's disease","volume":"15","author":"Pan","year":"2018","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0270","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.neulet.2010.10.063","article-title":"An investigation into the role of P-glycoprotein in Alzheimer's disease lesion pathogenesis","volume":"487","author":"Jeynes","year":"2011","journal-title":"Neurosci. Lett."},{"issue":"12","key":"10.1016\/j.addr.2022.114282_b0275","doi-asserted-by":"crossref","first-page":"e82505","DOI":"10.1371\/journal.pone.0082505","article-title":"Resistance to diet-induced obesity and associated metabolic perturbations in haploinsufficient monocarboxylate transporter 1 mice","volume":"8","author":"Lengacher","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2022.114282_b0280","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2174\/13816128113199990462","article-title":"Role of monocarboxylate transporters in drug delivery to the brain","volume":"20","author":"Vijay","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.addr.2022.114282_b0285","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1053\/j.gastro.2007.08.041","article-title":"Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation","volume":"133","author":"Thibault","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2022.114282_b0290","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1042\/bj3550725","article-title":"Association of 4F2hc with light chains LAT1, LAT2 or y+LAT2 requires different domains","volume":"355","author":"Br\u00d6er","year":"2001","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0295","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejps.2008.06.015","article-title":"Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2","volume":"35","author":"del Amo","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114282_b0300","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0022-3565(24)39291-2","article-title":"Expression and localization of multidrug resistant protein mrp2 in rat small intestine","volume":"293","author":"Mottino","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2022.114282_b0305","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/138920005774330657","article-title":"Coupling of conjugating enzymes and efflux transporters: Impact on bioavailability and drug interactions","volume":"6","author":"Jeong","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.addr.2022.114282_b0310","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FPC.0000000000000024","article-title":"PharmGKB summary: Very important pharmacogene information for UGT1A1","volume":"24","author":"Barbarino","year":"2014","journal-title":"Pharmacogenet. Genomics"},{"issue":"4","key":"10.1016\/j.addr.2022.114282_b0315","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0197-4580(00)00128-7","article-title":"Increased bilirubins and their derivatives in cerebrospinal fluid in Alzheimer's disease","volume":"21","author":"Kimpara","year":"2000","journal-title":"Neurobiol. Aging"},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0320","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/17425255.2.3.351","article-title":"Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition","volume":"2","author":"Jedlitschky","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.addr.2022.114282_b0325","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuron.2008.06.018","article-title":"Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta","volume":"59","author":"Adlard","year":"2008","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.addr.2022.114282_b0330","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.4049\/jimmunol.181.11.8044","article-title":"Multidrug resistance-associated transporter 2 regulates mucosal inflammation by facilitating the synthesis of hepoxilin A3","volume":"181","author":"Pazos","year":"2008","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.addr.2022.114282_b0335","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/micc.12186","article-title":"Restoration of cerebral and systemic microvascular architecture in APP\/PS1 transgenic mice following treatment with liraglutide\u2122","volume":"22","author":"Kelly","year":"2015","journal-title":"Microcirculation"},{"key":"10.1016\/j.addr.2022.114282_b0340","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/ajp.142.1.71","article-title":"Hyperammonemia in Alzheimer's disease","volume":"142","author":"Fisman","year":"1985","journal-title":"Am. J. Psychiatry"},{"issue":"2-3","key":"10.1016\/j.addr.2022.114282_b0345","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0278-5846(88)90042-5","article-title":"Oxazepam as a probe of hepatic metabolism in patients with Alzheimer's disease","volume":"12","author":"Fisman","year":"1988","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.addr.2022.114282_b0350","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1600-0773.1973.tb01494.x","article-title":"Effects of membrane stabilizers on glucuronidation and amino acid transport in cultures of rat hepatoma cells","volume":"32","author":"Dybing","year":"1973","journal-title":"Acta Pharmacol. Toxicol."},{"issue":"7","key":"10.1016\/j.addr.2022.114282_b0355","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1212\/WNL.40.7.1095","article-title":"Xenobiotic metabolism in Alzheimer's disease","volume":"40","author":"Steventon","year":"1990","journal-title":"Neurology"},{"issue":"8612","key":"10.1016\/j.addr.2022.114282_b0360","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0140-6736(88)90467-9","article-title":"Xenobiotic metabolism in motor neuron disease","volume":"332","author":"Steventon","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2022.114282_b0365","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1212\/WNL.39.7.883","article-title":"Xenobiotic metabolism in Parkinson's disease","volume":"39","author":"Steventon","year":"1989","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.addr.2022.114282_b0370","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1872312812666180816164626","article-title":"In vitro drug-drug interaction potential of sulfoxide and\/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone","volume":"12","author":"Giri","year":"2018","journal-title":"Drug Metab. Lett."},{"issue":"6","key":"10.1016\/j.addr.2022.114282_b0375","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1389557519666191119144100","article-title":"Medicinal thiols: Current status and new perspectives","volume":"20","author":"Pfaff","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"issue":"4","key":"10.1016\/j.addr.2022.114282_b0380","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.0022-3042.2001.00724.x","article-title":"Elevated hepatic and depressed renal cytochrome P450 activity in the Tg2576 transgenic mouse model of Alzheimer's disease","volume":"80","author":"Van Ess","year":"2002","journal-title":"J. Neurochem."},{"issue":"12","key":"10.1016\/j.addr.2022.114282_b0385","doi-asserted-by":"crossref","first-page":"e82554","DOI":"10.1371\/journal.pone.0082554","article-title":"Polymorphisms of CYP51A1 from cholesterol synthesis: Associations with birth weight and maternal lipid levels and impact on CYP51 protein structure","volume":"8","author":"Lewi\u0144ska","year":"2013","journal-title":"PLoS ONE"},{"issue":"1-4","key":"10.1016\/j.addr.2022.114282_b0390","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.prostaglandins.2006.05.004","article-title":"Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs)","volume":"82","author":"Inceoglu","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"4","key":"10.1016\/j.addr.2022.114282_b0395","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0149-2918(98)80127-6","article-title":"Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease","volume":"20","author":"Polinsky","year":"1998","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2022.114282_b0400","unstructured":"Exelon\u2122. European summary of product characteristics. Novartis Pharma AG, Basel, Switzerland (291998)."},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0405","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1021\/acschemneuro.9b00636","article-title":"Expression of Oatp2 in the brain and liver of Alzheimer disease mouse model","volume":"11","author":"Wen","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"11","key":"10.1016\/j.addr.2022.114282_b0410","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1021\/acschemneuro.0c00778","article-title":"Comment on \u201cExpression of Oatp2 in the brain and liver of Alzheimer disease mouse model\u201d","volume":"12","author":"Hagenbuch","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0415","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-131469","article-title":"Increased myeloperoxidase plasma levels in patients with Alzheimer's disease","volume":"39","author":"Tzikas","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.addr.2022.114282_b0420","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/157339510791111691","article-title":"Myeloperoxidase: The good, the bad, and the ugly","volume":"6","author":"Doris","year":"2010","journal-title":"Curr. Immunol. Rev."},{"issue":"6917","key":"10.1016\/j.addr.2022.114282_b0425","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0430","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1471-4159.2004.02527.x","article-title":"Neuronal expression of myeloperoxidase is increased in Alzheimer's disease","volume":"90","author":"Green","year":"2004","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.addr.2022.114282_b0435","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/17425255.2017.1271413","article-title":"Potential roles of myeloperoxidase and hypochlorous acid in metabolism and toxicity of alkene hydrocarbons and drug molecules containing olefinic moieties","volume":"13","author":"Zhang","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1-2","key":"10.1016\/j.addr.2022.114282_b0440","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cbi.2005.03.036","article-title":"Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4","volume":"155","author":"Kalgutkar","year":"2005","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.addr.2022.114282_b0445","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/s12877-020-01789-0","article-title":"Effects of kidney function, serum albumin and hemoglobin on dementia severity in the oldest old people with newly diagnosed Alzheimer\u2019s disease in a residential aged care facility: A cross-sectional study","volume":"20","author":"Wu","year":"2020","journal-title":"BMC Geriatr."},{"issue":"1","key":"10.1016\/j.addr.2022.114282_b0450","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/pmic.200300495","article-title":"Mining biomarkers in human sera using proteomic tools","volume":"4","author":"Zhang","year":"2004","journal-title":"Proteomics"},{"issue":"5","key":"10.1016\/j.addr.2022.114282_b0455","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0022-3956(99)00016-3","article-title":"Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer\u2019s disease","volume":"33","author":"Maes","year":"1999","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.addr.2022.114282_b0460","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/j.1532-5415.1997.tb02931.x","article-title":"Factors associated with cognitive impairment among older Italian inpatients","volume":"45","author":"Cattin","year":"1997","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"10.1016\/j.addr.2022.114282_b0465","doi-asserted-by":"crossref","first-page":"M18","DOI":"10.1093\/geronj\/43.1.M18","article-title":"The effect of age on serum albumin in healthy males: Report from the normative aging study","volume":"43","author":"Campion","year":"1988","journal-title":"J. Gerontol."},{"issue":"1-2","key":"10.1016\/j.addr.2022.114282_b0470","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s002280050078","article-title":"Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride) a potential agent for Alzheimer\u2019s disease","volume":"50","author":"Wood","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2022.114282_b0475","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.addr.2022.114282_b0480","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2011.09.069","article-title":"Impact of albumin on drug delivery - New applications on the horizon","volume":"157","author":"Elsadek","year":"2012","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.addr.2022.114282_b0485","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jconrel.2011.11.028","article-title":"Clinical impact of serum proteins on drug delivery","volume":"161","author":"Kratz","year":"2012","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.addr.2022.114282_b0490","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3233\/JAD-2011-102145","article-title":"Human serum transthyretin levels correlate inversely with Alzheimer's disease","volume":"25","author":"Han","year":"2011","journal-title":"J. Alzheimers Dis."},{"issue":"1-2","key":"10.1016\/j.addr.2022.114282_b0495","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0167-4838(00)00140-0","article-title":"The transthyretin-retinol-binding protein complex","volume":"1482","author":"Monaco","year":"2000","journal-title":"BBA-Protein Struct. M"},{"issue":"11","key":"10.1016\/j.addr.2022.114282_b0500","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.neurobiolaging.2007.04.007","article-title":"Transthyretin: A key gene involved in the maintenance of memory capacities during aging","volume":"29","author":"Brouillette","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.addr.2022.114282_b0505","first-page":"146","article-title":"Interaction of transthyretin with amyloid beta-protein: Binding and inhibition of amyloid formation","volume":"199","author":"Schwarzman","year":"1996","journal-title":"Ciba Found Symp."},{"key":"10.1016\/j.addr.2022.114282_b0510","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1532-5415.2008.01677.x","article-title":"Biomarkers of inflammation and malnutrition associated with early death in healthy elderly people","volume":"56","author":"Carriere","year":"2008","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.addr.2022.114282_b0515","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0014-5793(98)00234-8","article-title":"Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: Relation with the senile plaques and cytoskeleton biochemistry","volume":"425","author":"Merched","year":"1998","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.addr.2022.114282_b0520","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1179\/016164106X98035","article-title":"Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects","volume":"28","author":"Casta\u00f1o","year":"2006","journal-title":"Neurol. Res."},{"key":"10.1016\/j.addr.2022.114282_b0525","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JAD-2009-0966","article-title":"Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients","volume":"16","author":"Hansson","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.addr.2022.114282_b0530","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JAD-2008-14102","article-title":"Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia","volume":"14","author":"Gloeckner","year":"2008","journal-title":"J. Alzheimers Dis."},{"issue":"6","key":"10.1016\/j.addr.2022.114282_b0535","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1210\/jcem-68-6-1141","article-title":"Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin","volume":"68","author":"Munro","year":"1989","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0540","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/jgs.16954","article-title":"Kidney function and cognitive decline in older adults: Examining the role of neurodegeneration","volume":"69","author":"Guerville","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.addr.2022.114282_b0545","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1097\/01.ASN.0000131529.60019.FA","article-title":"Moderate renal impairment and risk of dementia among older adults: The cardiovascular health cognition study","volume":"15","author":"Seliger","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2022.114282_b0550","first-page":"628A","article-title":"Anemia as a risk factor for incident dementia in hemodialysis patients","volume":"13","author":"Murray","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2022.114282_b0555","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000058418","article-title":"Psychiatric disorders among patients undergoing hemodialysis therapy","volume":"91","author":"Fukunishi","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.addr.2022.114282_b0560","first-page":"697A","article-title":"Dementia in aged dialyzed patients and ethics: Study of cognitive functions in 120 patients","volume":"13","author":"Charmes","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.addr.2022.114282_b0565","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0272-6386(97)90563-1","article-title":"Prevalence, recognition, and implications of mental impairment among hemodialysis patients","volume":"30","author":"Sehgal","year":"1997","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"10.1016\/j.addr.2022.114282_b0570","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1046\/j.1523-1755.2003.00101.x","article-title":"Elevated risk of stroke among patients with end-stage renal disease","volume":"64","author":"Seliger","year":"2003","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.addr.2022.114282_b0575","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1053\/ajkd.2002.36321","article-title":"Relationship of renal function to homocysteine and lipoprotein(a) levels: The frequency of the combination of both risk factors in chronic renal impairment","volume":"40","author":"Parsons","year":"2002","journal-title":"Am. J. Kidney Dis."},{"issue":"7","key":"10.1016\/j.addr.2022.114282_b0580","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa011613","article-title":"Plasma homocysteine as a risk factor for dementia and Alzheimer\u2019s disease","volume":"346","author":"Seshadri","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114282_b0585","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0197-4580(95)00066-N","article-title":"Are reactive oxygen species involved in Alzheimer\u2019s disease?","volume":"16","author":"Benzi","year":"1995","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.addr.2022.114282_b0590","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000054752","article-title":"Nutritional factors in cerebral aging and dementia: Epidemiological arguments for a role of oxidative stress","volume":"20","author":"Deschamps","year":"2001","journal-title":"Neuroepidemiology"},{"issue":"13","key":"10.1016\/j.addr.2022.114282_b0595","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0600","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/aje\/kwp426","article-title":"A prospective study of albuminuria and cognitive function in older adults: The Rancho Bernardo study","volume":"171","author":"Jassal","year":"2010","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.addr.2022.114282_b0605","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0168-8227(01)00300-X","article-title":"Total homocysteine and cognitive deterioration in people with type 2 diabetes","volume":"55","author":"de Luis","year":"2002","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.addr.2022.114282_b0610","first-page":"1","article-title":"Plasma ICAM-1 and VCAM-1 levels in type 2 diabetic patients with and without microalbuminuria","volume":"99","author":"Bruno","year":"2008","journal-title":"Minerva Med."},{"key":"10.1016\/j.addr.2022.114282_b0615","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1532-5415.2007.01158.x","article-title":"Cognitive decline and markers of inflammation and hemostasis: The Edinburgh Artery Study","volume":"55","author":"Rafnsson","year":"2007","journal-title":"J. Am. Geriatr. Soc."},{"issue":"6","key":"10.1016\/j.addr.2022.114282_b0620","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/gerona\/glu189","article-title":"Cystatin C and cognitive impairment 10 years later in older women","volume":"70","author":"Slinin","year":"2015","journal-title":"J. Gerontol. A"},{"issue":"1","key":"10.1016\/j.addr.2022.114282_b0625","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1053\/ajkd.2001.20628","article-title":"Serum cystatin C concentration as a marker of renal dysfunction in the elderly","volume":"37","author":"Fliser","year":"2001","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"10.1016\/j.addr.2022.114282_b0630","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3233\/JAD-170480","article-title":"Estimated glomerular filtration rate is not associated with Alzheimer's disease in a Northern Ireland cohort","volume":"60","author":"Paterson","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.addr.2022.114282_b0635","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1471-4159.2001.00379.x","article-title":"Induction of NADPH cytochrome P450 reductase by the Alzheimer beta-protein. Amyloid as a \u201cforeign body\u201d","volume":"78","author":"Pappolla","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.addr.2022.114282_b0640","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12086","article-title":"Renal drug metabolism in humans: The potential for drug\u2013endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)","volume":"76","author":"Knights","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.addr.2022.114282_b0645","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0006-2952(96)00821-0","article-title":"Cytochrome P450 4A and 2E1 expression in human kidney microsomes","volume":"53","author":"Amet","year":"1997","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.addr.2022.114282_b0650","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1016\/j.xphs.2019.02.016","article-title":"Increased expression of renal drug transporters in a mouse model of familial Alzheimer's disease","volume":"108","author":"Pan","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114282_b0655","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.V881213","article-title":"Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney epithelial cells","volume":"8","author":"Schaub","year":"1997","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2022.114282_b0660","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/j.1476-5381.2011.01672.x","article-title":"Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells","volume":"165","author":"Fahrmayr","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.addr.2022.114282_b0665","doi-asserted-by":"crossref","first-page":"G656","DOI":"10.1152\/ajpgi.00383.2001","article-title":"Increased renal expression of bilirubin glucuronide transporters in a rat model of obstructive jaundice","volume":"282","author":"Tanaka","year":"2002","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.addr.2022.114282_b0670","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.14336\/AD.2020.0217","article-title":"Alteration of metabolic profile and potential biomarkers in the plasma of Alzheimer's disease","volume":"11","author":"Shao","year":"2020","journal-title":"Aging Dis."},{"key":"10.1016\/j.addr.2022.114282_b0675","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.addr.2022.114282_b0680","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2133\/dmpk.DMPK-10-RG-004","article-title":"Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: The role of renal organic cation transporter OCT2","volume":"25","author":"Kurata","year":"2010","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.addr.2022.114282_b0685","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by organic anion transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114282_b0690","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/metabo7020028","article-title":"Metabolomic profiling of bile acids in clinical and experimental samples of Alzheimer\u2019s disease","volume":"7","author":"Pan","year":"2017","journal-title":"Metabolites"},{"issue":"7","key":"10.1016\/j.addr.2022.114282_b0695","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbadis.2006.05.011","article-title":"Renal elimination of p-aminohippurate (PAH) in response to three days of biliary obstruction in the rat: The role of OAT1 and OAT3","volume":"1762","author":"Brandoni","year":"2006","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"issue":"5","key":"10.1016\/j.addr.2022.114282_b0700","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/hep.21142","article-title":"Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction","volume":"43","author":"Brandoni","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.addr.2022.114282_b0705","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.dadm.2017.01.005","article-title":"Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis","volume":"7","author":"Santos","year":"2017","journal-title":"Alzheimers Dement (Amst)"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22001727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22001727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:27:00Z","timestamp":1759210020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X22001727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":141,"alternative-id":["S0169409X22001727"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114282","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered peripheral factors affecting the absorption, distribution, metabolism, and excretion of oral medicines in Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114282"}}